EN

Announcements & Notices

All 2024 2023 2022 2021
Total:98 items
Total: 98 items
All Announcements and Notices Monthly Returns
All
  • 29
    2024-04
    Announcements and Notices
    APPOINTMENT OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
  • 25
    2024-04
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ODD BY FDA
  • 24
    2024-04
    Announcements and Notices
    RESIGNATION OF JOINT COMPANY SECRETARY
  • 16
    2024-04
    Announcements and Notices
    NOTICE OF THE ANNUAL GENERAL MEETING
  • 10
    2024-04
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - 3 Pre-clinical Research Results Presented at AACR 2024
  • 09
    2024-04
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - Pimicotinib (ABSK021) Patient Enrollment Completed
  • 13
    2024-03
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
  • 12
    2024-03
    Announcements and Notices
    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
  • 28
    2024-02
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DELIVERED ORAL PRESENTATION OF PRELIMINARY FIRST-IN-HUMAN TRIAL RESULTS OF ITS HIGHLY SELECTIVE FGFR2/3 INHIBITOR ABSK061 AT THE 2024 ESMO TAT
  • 26
    2024-02
    Announcements and Notices
    DATE OF BOARD MEETING
Go to Page
Supplied by:Realxen.net
Terms of Service | Cookie Policy | Privacy Policy

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号   

Lang
En
繁
简